Date
2022/7/5

2022/7/12

2022/7/19

Presenter

Title

古本Teclistamab in Relapsed or Refractory Multiple Myeloma

宮﨑

⾻髄系腫瘍の新しい分類について

児嶋

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma⻑井A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

クリクラ学⽣ INCB84344-201:Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

JournalYear

Vol

Page

N Engl J Med

2022

387(18)1721

N Engl J Med

2022

386(26)2482-2494

Nat Med202228(6)1212-1223

Blood Adv2022686)

1742-1753

蓬莱Molecular international prognostic scoring system for myelodysplastic symdromes

Nejm Evid2022

1(7)

勝岡

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Blood

2022

139(6)

835-844加藤

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood

2022

140(11)1229-1253

2022/9/6

勝岡

第84回⽇本⾎液学会 予⾏2022/9/13

⻄村

第84回⽇本⾎液学会 予⾏

古本

第84回⽇本⾎液学会 予⾏Lancet Oncol

202122(4)512-524

Nat Med2022

28(10)

2124-2132

Lancet Oncol

2022

23(8)

1055-1065

Blood

2022

140(10)1094-1103

Haematologica

2022

107(11)2675-2684

N Engl J Med

2022

386(23)2188-2200

Lancet Haematol.

2022

9(9)

e660-e669

Blood

2022

140(14)1621-1634

2022/7/26

2022/9/20

松本
⽷永

2022/9/27

2022/10/4

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of amulticentre, randomised, open-label, phase 3 study
第84回⽇本⾎液学会 予⾏

⼀瀬Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

安東

第84回⽇本⾎液学会 予⾏

勝岡

第84回⽇本⾎液学会 予⾏加藤2022/10/11

2022/10/18

古本

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm,multicentre, phase 2 study

佐藤TET2-mutant clonal hematopoiesis and risk of gout

勝岡

第8回⽇本HTLV-1学会 予⾏2022/10/25

第84回⽇本⾎液学会 報告会

2022/11/1

第84回⽇本⾎液学会 報告会

2022/11/8

児嶋蓬莱

2022/11/15

2022/11/22

2022/11/29

⻄村Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter
GELTAMO/FIL study
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): amulticentre, single-arm, phase 2 trial

宮﨑Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis

松本

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

Blood

2022

140(18)

1964-1971

⻑井Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

Nat Med

2022

28(9)

1872-1882

J Haematol Oncol

2022

15(1)

126

Clin Infect Dis

2022

75(4)

690-701

清⽔坂本

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical
Trial